StockData

NewAmsterdam Pharma vs Viridian Therapeutics, Inc.\DE

NAMS and VRDN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NAMS and VRDN compare

Viridian Therapeutics, Inc.\DE grew revenue faster over the last twelve months (23220% versus −88.9% for NewAmsterdam Pharma).

Viridian Therapeutics, Inc.\DE keeps more of each dollar of sales as profit, with a net margin of −544% compared with −3644% at NewAmsterdam Pharma.

NewAmsterdam Pharma scores higher on the StockData Score (6 against 4 for Viridian Therapeutics, Inc.\DE), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNAMSVRDN
Size and price
Market cap–$3.4B
Share price$19.39$30.06
Change, 1 year−49.4%4.5%
Change, 5 years98.1%64.3%
Beta (5Y)1.57−0.13
Employees100252
StockData Score
Total score6 (better)4
Valuation score00
Growth score02 (better)
Performance score11
Health score5 (better)1
Dividend score00
Valuation
P/S–47.9×
P/B–5.1×
FCF yield–−9.8%
Fair value–$8.47
Margin of safety–−255%
Growth
Revenue growth (TTM)−88.9%23220% (better)
Revenue growth, 5Y average–132%
Profitability
Operating margin−3432%−570% (better)
Net margin−3644%−544% (better)
FCF margin−2018%−471% (better)
Return on equity−36.8% (better)−65.7%
Return on invested capital−1046%–
Financial health
Debt / equity0.00–
Interest coverage–−26.0×
Current ratio9.0316.95 (better)
Altman Z-score–2.65
Piotroski F-score34 (better)
Dividends and buybacks
Buyback yield–−1.7%
Shareholder yield–−1.7%
Ownership
Held by institutions–120%
Held by insiders22.0%21.8%
Insider net buying, 12 months−$63.0M$19.6M (better)
Short interest, % of float–19.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.